Pharmacological management of cannabinoid hyperemesis syndrome: an update of the clinical literature.

CHS is frequently unrecognized by clinicians, leading to extensive and unnecessary testing and treatment. Directed questions about cannabis use and the effect of hydrothermotherapy on CHS symptoms frequently confirm the diagnosis, enabling appropriate pharmacotherapy and referral to addiction treatment. CHS prevalence will continue to rise in parallel with increasing worldwide cannabis use and potency. Classic antiemetics may be tried initially but often fail to alleviate CHS. Antipsychotics (such as haloperidol), benzodiazepines, and/or capsaicin cream appear to be the most efficacious in the treatment of this unique disorder.